Images List Premium Download Classic

Psychiatric

Psychiatric-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders
July 12, 2018 - N°20180193362

And the pharmaceutically acceptable salts thereof, wherein r1, r2, r2′, and x are as defined as set forth in the specification, for use in treating cognitive deficits and/or psychiatric disorders, such as those associated with neurological or neurodegenerative disorders, psychiatric or mood disorders, and hiv-associated neurocognitive disorders (hand). Compounds having formula (i) are prodrugs that release glutamine analogs, ...
Alkylated tetrahydroisoquinolines for binding to central nervous system receptors
Florida A&m University
July 12, 2018 - N°20180193330

Derivatives of 1,2,3,4-tetrahydroisoquinoline (thiq) having the general formula a-(ch2)n—b are provided, wherein a is thiq or a substituted derivative thereof and b is an aryl, cycloalkylaryl, or cycloalkyl group, wherein a and b are linked to each other by an alkyl or substituted alkyl chain. The compounds are useful as selective ligands (agonists or antagonists) of ...
System and method for modifying biometric activity using virtual reality therapy
Storyup, Inc.
July 05, 2018 - N°20180190376

Systems and methods for using virtual reality content as therapeutic treatment of psychological, psychiatric or medical conditions of a user are provided. The system may comprise a vr device for displaying the vr content to the user and one or more biometric monitors for monitoring the user's biometrics before, during and/or after exposure to the vr content.
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
Emory University
July 05, 2018 - N°20180186762

In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to bdnf and trkb activity, such as psychiatric disorders, depression, post-traumatic stress disorder, and autism spectrum disorders, stroke, ...
Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
Embera Neurotherapeutics, Inc.
July 05, 2018 - N°20180185375

The present invention features a composition comprising a first agent and a second agent for treating disorder associated with aberrant activity in the hpa axis like an addiction to a substance (e.g., cocaine, amphetamines, methamphetamine, methylphenidate, heroin, codeine, hydrocodone, nicotine, alcohol, prescription medication (e.g., percodan®, percoset®), marijuana, tobacco, methadone, food), addiction to an activity (e.g., ...
Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor ...
Vanderbilt University
June 28, 2018 - N°20180179205

In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m1 (machr m1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Substituted triazolo bicyclic compounds as pde2 inhibitors
Merck Sharp & Dohme Corp.
June 21, 2018 - N°20180169072

The present invention is directed to substituted triazolo bicyclic compounds of formula i which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's ...
Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
Merck Sharp & Dohme Corp.
June 14, 2018 - N°20180162874

The present invention is directed to pyrimidine carboxamide compounds of formula i which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's disease, ...
Pyridine and pyrimidine derivatives
June 14, 2018 - N°20180162824

The compounds of formula i may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.. .
Heterocyclic compounds for the treatment of neurological and psychological disorders
Alkermes Pharma Ireland Limited
June 14, 2018 - N°20180162816

Lactam compounds of formula i and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.. .
Use of carbonic anhydrase inhibitors for treatment of neurological and psychiatric disorders
New York University
June 14, 2018 - N°20180161339

The invention is directed to the use of carbonic anhydrase inhibitors for treatment of neurological and psychiatric disorders.. .
Sublingual administration of riluzole
Biohaven Pharmaceutical Holding Company Limited (b
June 07, 2018 - N°20180153862

Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided.
Sublingual formation of riluzole
Biohaven Pharmaceutical Holding Company Limited (b
June 07, 2018 - N°20180153794

Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided.
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Heteroarylphenoxy benzamide kappa opioid ligands
May 31, 2018 - N°20180148432

And pharmaceutically acceptable salts thereof wherein the variables r1, r2, r3, r4, r9, x, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (κ-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder ...
Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and ...
Acorda Therapeutics, Inc.
May 31, 2018 - N°20180147193

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as ms, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.. .
Bicyclic heterocyclic compounds as pde2 inhibitors
Merck Sharp & Dohme Corp.
May 24, 2018 - N°20180141952

The present invention is directed to dihydropyrazolopyrimidinone compounds of formulas (i) and (ii) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's ...
Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration
Phovitreal Pty Ltd
May 24, 2018 - N°20180140561

A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.. .
Feedback brain stimulation to enhance sleep spindles, modulate memory and cognitive function, and treat psychiatric ...
The University Of North Carolina A! Chapel Hill
May 24, 2018 - N°20180140249

The present invention relates to methods for modulating bursts of oscillatory brain activity, such as sleep spindles, in a subject. The invention further relates to methods of improving memory or cognitive function in a subject and method of modulating or enhancing the frequency of occurrence, structure, amplitude, and/or synchronization of sleep spindles in a subject by detecting a burst ...
6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
Msd R & D (china) Co. Ltd.
May 17, 2018 - N°20180134712

The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (i) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (pde2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, parkinson's disease, parkinson's disease dementia (pdd), or huntington's disease, ...
Ligands selective to alpha 6 subunit-containing gabaa receptors and their methods of use
University Of Belgrade - Faculty Of Pharmacy
May 17, 2018 - N°20180134698

Provided herein are novel pyrazolo-quinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, huntington's disease and nocturnal enuresis;depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.. .
Pupil distortion measurement and psychiatric diagnosis method
May 17, 2018 - N°20180132775

A prediction, diagnosis, or suggesting of a diagnosis of a psychiatric disorder is made based in embodiments of the disclosed technology by determining a shape of one or both pupils in an image of a patient. Such a diagnosis can be made in real-time by diagnosing the patient, or by viewing a digitized version of the patient's face as part ...
Loading